| Accession |
PRJCA013863 |
| Title |
A Phase II clinical study to advanced cervical cancer subjects who have failed or cannot tolerate first-line or above platinum-based chemotherapy |
| Relevance |
Medical |
| Data types |
Biomarker
|
| Organisms |
Homo sapiens
|
| Description |
This is a randomized,doubie-blind,controlled,parallel-cohort Phase II clinicial study,which is planned to enroll 174 subjects with advanced cervical cancer who have failed or can not tolerate first-line or above platinum-based chemotherapy.The primary endpoints is Objective response rate (ORR) by Independent Radiological Review Committee(IRRC) according to the Response Evaluation Criteria in Solid Tumors(RECIST) V1.1 |
| Sample scope |
Monoisolate |
| Release date |
2023-04-01 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| innoventbio
|
|
NA
|
|
|
|
| Submitter |
Qinglei
Gao (qingleigao@hotmail.com)
|
| Organization |
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Submission date |
2022-12-13 |
